Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...
The antibody-drug conjugate (ADC) manufacturing landscape offers the potential to leverage significant opportunities for cancer treatment, but faces complex challenges. Nevertheless, the ADC market ...
SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE)-- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, ...
Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...
ADCs have transformed bladder cancer treatment, but challenges like toxicity management and high costs remain significant hurdles. ADCs vary in components and mechanisms, influencing outcomes and ...
Stability and toxicity are two of the major challenges. First, linker stability issues result in the immediate release of the drug payload following administration, which results in persistent high ...
A four-month FDA delay prompted a cash-strapped biotech company to shutter. The White House’s proposed NIH cuts are drawing ...
The clinical results from several trials suggest that patients get a high response rate from enfortumab vedotin (the antibody-drug conjugate) that is made durable from pembrolizumab (the checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results